novel coronavirus pneumonia (COVID-19)
Conditions
Interventions
Ursodeoxycholic acid (UDCA) treatment group:Conservative treatment + oral administered ursodeoxycholic acid (10-15 mg/kg/d, twice a day, maximum dose 0.25g, twice a day, for 5 days)
Sponsors
Xiamen Children's Hospital
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Confirmed mild or moderate SARS-CoV-2 infection; 2. No gender limit, aged 1 month to 18 years; 3. Confirmed SARS-CoV-2 infection within 72 hours prior to enrollment; 4. Normal function of major organs (heart, liver, lungs, kidneys); 5. The guardians were fully informed and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Serious diseases such as tumor, immune deficiency or organ transplantation; 2. Patients with convulsion; 3. Infected persons with other pathogens; 4. Patients taking antibiotics, hormones and immunosuppressants at the same time; 5. Ursodeoxycholic acid is contraindicated; 6. The researcher believes that it is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of participants with clinical improvement;Ct value of COVID-19 nucleic acid in throat swabs; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum ACE2 level;Serum cytokine level; | — |
Countries
China
Contacts
Public ContactYu Hui
Xiamen Children's Hospital
Outcome results
None listed